CCTG, Kingston, Canada.
GOG, Philadelphia, USA.
Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010.
This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the consensus process, which is intended to guide future research initiatives.
本手稿报告了关于新诊断和复发性上皮性卵巢癌（EOC）患者临床试验设计和实施的共识声明，这些共识是在 2015 年 11 月于东京举行的第五届卵巢癌共识会议（OCCC）上经过审议后得出的。在会议之前确定了三个需要讨论的重要问题，并在会议期间达成了共识：（i）在初始治疗之前需要评估的最重要因素是什么？（ii）在复发性疾病中需要特别评估的最重要因素是什么？（iii）对于特殊患者亚群是否有特殊考虑？此外，我们报告了在共识过程中编制的重要未满足需求清单，旨在指导未来的研究计划。
